Full Year 2024 Results Key Financial Results Revenue: US$22.3m (down 12% from ...

Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) saw some unusual options trading on Thursday. Traders acquired ...

We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a ...

Shares of Capricor Therapeutics (CAPR) are trading up by about 13% on Thursday noon after the company announced ...

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Capricor Therapeutics ...

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Capricor Therapeutics (CAPR – Research Report), with ...

AlphaQuest LLC purchased a new position in Capricor Therapeutics Inc (NASDAQ:CAPR – Free Report) during the fourth quarter, ...

Capricor Therapeutics (CAPR) released expectation-beating results for the fourth quarter, sending the shares up over 5% in aftermarket trading.

Capricor Therapeutics, Inc.’s CAPR share price has surged by 17.51%, which has investors questioning if this is right time to ...

Q4 2024 Management View CEO Linda Marban highlighted the acceptance by the FDA of Capricor's Biologics License Application (BLA) for deramiocel, targeting treatment of Duchenne muscular dystrophy (DMD ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Capricor Therapeutics Inc. (CAPR) on Wednesday reported a loss of $7.1 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a ...

The biotechnology company posted adjusted earnings per share of -$0.16 for Q4, beating analyst estimates by $0.01. Revenue came in at $11.13 million, significantly above the consensus forecast of ...